Approved !

U.S. Patent and Trademark Of Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Under the P number,	Paperwork Reduction Act				Complete if Known	
	INFORMATION D	SCLOS	AAIT C	Application Number	10/522,130 January 19, 2005	
	STATEMENT BY	1	AUS 1 1 Zuco	First Named Inventor Group Art Unit Examiner Name	Murray Goodman	
Sheet	(use as many sheet	of	2 PAD PARAD	Attorney Docket Number	SDUC1100J-1 (041673-3109)	

				U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
		U.S. Patent		Name of Patentee or Applicant of	Date of Publication of Cited Document	Where Relevant Passages or Relevant
Examiner Initials*	Cite No.	Number	Kind Code ² (if known)	Cited Document	MM-DD-YYYY	Figures Appear
	1					

					DREIGN PATENT DOCUMENT	Date of Publication of Cited Document	Pages, Columns, Lines. Where Relevant	
Examiner Initials*	Cite No.1	Office	oreign Patent [Kind Code	Name of Patentee or Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	T
	A1	wo	91/09958	(if known)	Whitehead Institute for Blomedical Research	07-11-1991		
	A2	wo	94/04686		Blogen, Inc.	03-03-1994		_
	A3	WO	98/52614		The Board of Trustees of	11-26-1998		
					the Leland Stanford Junior University			士

		NON PATENT LITERATURE DOCUMENTS	_			
Examiner Initials*	Cite No.1	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the article (when ap				
Minaro	A4	BUSCHLE, M. et al., Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA., 94, p. 3256-3261 (1997).				
	A5	EMI, N. et al., Gene Transfer Mediated by Polyarginine Requires a Formation of Big Carrier-Complex of DNA Aggregate, Biophys. Res. Commun., 231, p. 421-424 (1997).				
• - 	A6	FEICHTINGER, L. et al., Triurethane-Protected Guanidines and Triffydiurethane-Protected Guanidines: New Reagents for Guanidinylation Reactions, J. Org. Chem., 63, p. 8432 (1998).				
	A7	LEONETTI, JP. et al., Biological Activity of Oligonucleotide-Poly(L-lysine) Conjugates: Mechanism of Cell Uptake, Bioconjugate Chem., 1, p. 149-153 (1990).				
	A8	MITCHELL, D.J. et al., Polyargine enters cells more efficiently than other polycationic homopolymers, J. Peptide Res., 55 p. 318-325 (2000).	_			
	A9	MURPHY, J.E. et al., A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery, Proc. Natl. Acad. Sci. USA., 95, p. 1517-1522 (1998).				

			02/19/2009
Examiner	/David Lukton/	Date Considered	
Signature	to reference considered, whether or not citation is in conformance with i	MPEP 609. Draw line through citation i	f not in conformance and not

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandra, VA 22313-1459.

considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3) *For Japanese patent documents, the indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if *Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if *Control because Translation is distributed.*

MODIFIED PTO/SB/08 (08-00) through 10/31/2002. OMB 0651-0031 Approved U.S. Patent and Trademark On U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

nber.	444000	70		Complete if Known
Substitu	te for form 1449B/P	"COIPA	Application Number	10/522,130
INFORM	ATION DISCLOS	DRE	Filing Date	January 19, 2005
STATEN	ENT BY APPLI		First Named Inventor	Murray Goodman
	1	AUS 1 1 2005	Group Art Unit	
	1	5	Examiner Name	
(use as ma	ny sheets as ned	essary)		SDUC1100J-1 (041673-3109)
heet 2	of	PANGHADY	Attorney Docket Number	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.)	T ⁶
	A10	PEPINSKY, R.B. et al., Specific Inhibition of a Human Papillomavirus E2 <i>Trans</i> -Activator by Intracellular Delivery of Its Repressor, DNA Cell Blol., 13, p. 1011-1019 (1994).	
	A11	RYSER, H.JP., A Membrane Effect of Basic Polymers dependent on Molecular Size, Nature (London), 215, p. 934-936 (1967).	
	A12	RYSER, N.JP. et al., Conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of method (1978).	
	A13	SCHWARZE, S.R. et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, 285, p. 1569-1572 (1999).	
	A14	SHEN, W., et al., Conjugation of poly-L-lysine to albumin and horseradish peroxides: A novel method of enhancing the cellular uptake of proteins, Proc. Nat. Acad. Sci. USA., 75, p. 1872-1876 (1978).	†-
	A15	VOCERO-AKBANI, A.M. et al., Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein, Nat. Med., 5, p. 29-33 (1999).	
	A16	WENDER, P.A. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA., 97, p. 13003-13008 (2000).	+

Examiner	/David Lukton/	Date Considered	02/19/2009
Signature	the constitution is in conformance with MPEP	609. Draw tine through citation	if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if for the patent of the pat